Recent Advances in Movement Disorders

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.

Cristian Falup-Pecurariu is Head of the Department of Neurology, County Clinic Hospital from Brasov, and is Full Professor of Neurology at the Transilvania University from Brasov, Romania. He received his medical degree from the University of Medicine and Pharmacy “Iuliu Hatieganu from Cluj-Napoca. He hold a 1 year fellowship of the European Neurological Society in movement disorders at Hospital Clinic, University of Barcelona, Spain. During his career Cristian Falup-Pecurariu was President of the European Association of Young Neurologists and Trainees (EAYNT), EAYNT Liasion Officer with World Federation of Neurological Society, co-representative of Europe on the International Working Group for Young Neurologists and Trainees (World Federation of Neurology). He was also Secretary of the EFNS/MDS-ES Panel on Movement Disorders, member of the Educational Committee of MDS-ES, member of the MDS Leadership Task Force and European Academy of Neurology Scientific Panel Movement Disorders, member of the Teaching Course sub-Committee of the European Academy of Neurology (EAN), currently being member of the Program Committee of EAN. Falup-Pecurariu is former Chair of the Education Committee of the MDS-ES, former member of the Executive Committee of MDS-ES, former member of the International Executive Committee of MDS. He is the initiator and Course Director of the Movement Disorders Teaching Course held in Brasov (12th editions). His research focuses on motor and non-motor aspects of Parkinson’s diseases.

Santiago Perez-Lloret MD PhD, is a leading expert in neurophysiology and neuropharmacology with more 130 papers published in international medical journals (Scopus H-index=35). After obtaining his MD and PhD in the University of Buenos Aires, Argentina, he pursued master courses in pharmacoepidemiology, clinical pharmacology and biostatistics at the Universities of Toulouse, Bordeaux and Paris, France. Dr. Perez-Lloret is an Assistant professor of Neurophysiology at the Medicine School of the University of Buenos Aires and a Senior Researcher at the Argentinean National Research Council. He is the director of the Health, Quality of Life, and Environment Unit at the Catholic University of Argentina and Editor-in-Chief of the Neurodegenerative Diseases International journal. He is a Fulbright scholar since 2002 and member of the Sigma Xi society. He is a member of the Evidence-Based Medicine Committee of the International Parkinson’s Disease and Movement Disorder Society (MDS).

Dr. Matilde Otero-Losada graduated at the School of Pharmacy and Biochemistry, University of Buenos Aires (UBA) Argentina, pursued her studies in Neuropharmacology getting her Sci.D. in Neuropharmacology (UBA, Argentina) and completing her Ph.D. in Psychiatry at the Wolverhampton University, WLV, UK. Her following studies in Psychometrics and Statistical Methods, Radioisotopes and Radiochemistry, Signal Processing and Microcomputers, took her to the University of California San Diego (UCSD) for training in human Psychophysics. Back to Argentina, she carried on studying smell, taste and trigeminal perception at the Hospital de Clínicas, UBA. Focused on the study of metabolic syndrome, soft drinks and cardiovascular-renal morbidity for the last ten years, in the last two years she is back to her roots: Neurosciences. With over 90 papers published in prestigious journals indexed in PubMed, Embase and Scopus and book chapters authored, as Senior Researcher of the National Research Council (Argentina), she customarily reviews manuscripts and is acknowledged in scientific writing, and editorial capacities.